title: [Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer].
abstract: Numerous lesions of the prostate, such as atrophy, adenomatous atypical hyperplasia (adenosis) or PIN can be misdiagnosed with prostatic cancer, and confused with ASAP, leading to perform additional biopsies. In such lesions, the pathologist can perform an immunohistochemical study with the anti-high molecular weight cytokeratin antibody CK903 (34bE12), which confirms the absence of basal cells and supports the diagnosis of prostatic cancer.
  
  
  OBJECTIVE
  To compare markers of basal cells (cytokeratin 5/6, p63) and the marker of prostatic carcinomatous glands (p504s) or alpha methylacyl-CoA racemase (AMACR).
  
  
  METHODS
  Retrospective study of 44 cases of paraffin-embedded prostatic specimens (36 biopsies, 4 PER, 1 adenomectomy and 3 radical prostatectomies), consisting in 20 cases of prostatic carcinomas (2 intraductal, 12 Gleason 6 (3+3), 4 Gleason 7 (4+3), 2 Gleason 8 (4+4)), 11 ASAP, 9 PIN (2 low grade, 7 high grade (2 isolated)), and 10 benign lesions (8 atrophy, 1 atypical adenomatous hyperplasia and 1 case of clear cell cribriform hyperplasia). All cases were tested with antibodies to CK 5/6, and with a cocktail to p63 and p504s, after heat antigenic retrieval on NEXES Ventana processor.
  
  
  RESULTS
  Basal cells of normal prostatic glands stained with CK5/6 and p63 in 91,3% and 100% of cases, independently from the fixation procedure (Bouin or Formalin). Carcinomas had a p63-/p504s+ profile, PIN were p63+/p504s+, and benign lesions were p63+/p504s-. We observed an increase in sensitivity: p63/p504s (100%), CK5/6 (80%), p63 (90%), p504s (95%), and specificity: p53/p504s (90%), CK5/6 (87.5%), p63 (90.5%), p504s (90.9%).
  
  
  CONCLUSIONS
  Our results show that the use of a cocktail to p63/p504s is more specific than the use of CK5/6 alone this technique supports a diagnosis of prostatic cancer in 40% of cases previously considered as ASAP.
authors.affiliation: Service de Pathologie, Hôpital Foch, Suesnes. v.molinie@hopital-foch.org
authors.forename: Vincent
authors.initials: V
authors.lastname: Molinié
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Hervé
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Lugagne-Delpon
authors.forename: François
authors.initials: F
authors.lastname: Saporta
authors.forename: Laurent
authors.initials: L
authors.lastname: Yonneau
authors.forename: Henry
authors.initials: H
authors.lastname: Botto
authors.forename: Anne Catherine
authors.initials: AC
authors.lastname: Baglin
mesh_terms: D000906:Antibodies / Q000032:analysis*; D004268:DNA-Binding Proteins; D016147:Genes, Tumor Suppressor; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D010750:Phosphoproteins / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000175:diagnosis*; D019998:Racemases and Epimerases / Q000276:immunology*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015534:Trans-Activators / Q000276:immunology*; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins
chemical_list: D000906:Antibodies; D004268:DNA-Binding Proteins; D010750:Phosphoproteins; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase